Cardiovascular disease prevention in women: A rapidly evolving scenario

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 12, 2012, Pages 1013-1018

  Stranges, S ^a   Guallar, E ^b,c  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

Cardiovascular disease; Clinical trials; Gender; Guidelines; Prevention; Women

Indexed keywords

CARDIOVASCULAR DISEASE; FEMALE; HUMAN; LIFESTYLE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SHORT SURVEY; UNITED STATES;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; LIFE STYLE; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; UNITED STATES;

EID: 84870437507     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2012.10.001     Document Type: Short Survey

References (63)

1. Howard B.V., Taskinen M.R. CVD in women. Nutr Metab Cardiovasc Dis 2010, 20:377-378.
2. Roger V.L., Go A.S., Lloyd-Jones D.M., Adams R.J., Berry J.D., Brown T.M., on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
3. Ford E.S., Capewell S. Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care. Annu Rev Public Health 2011, 32:5-22.
4. Ford E.S., Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. J Am Coll Cardiol 2007, 50:2128-2132.
5. Mosca L., Barrett-Connor E., Wenger N.K. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation 2011, 124:2145-2154.
6. Panico S., Mattiello A. Epidemiology of cardiovascular diseases in women in Europe. Nutr Metab Cardiovasc Dis 2010, 20:379-385.
7. Zhang Y. Cardiovascular disease in American women. Nutr Metab Cardiovasc Dis 2010, 20:386-393.
8. Hu D., Yu D. Epidemiology of cardiovascular disease in Asian women. Nutr Metab Cardiovasc Dis 2010, 20:394-404.
9. Tejero M.E. Cardiovascular disease in Latin American women. Nutr Metab Cardiovasc Dis 2010, 20:405-411.
10. Shara N.M. Cardiovascular disease in Middle Eastern women. Nutr Metab Cardiovasc Dis 2010, 20:412-418.
11. Laccetti R., Pota A., Stranges S., Falconi C., Memoli B., Bardaro L., et al. Evidence on the prevalence and geographic distribution of major cardiovascular risk factors in Italy. Public Health Nutr 2012, 30:1-11.
12. Mosca L., Benjamin E.J., Berra K., Bezanson J.L., Dolor R.J., Lloyd-Jones D.M., et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation 2011, 123:1243-1262.
13. Mosca L., Grundy S.M., Judelson D., King K., Limacher M., Oparil S., et al. Guide to preventive cardiology for women. AHA/ACC scientific statement, consensus panel statement. Circulation 1999, 99:2480-2484.
14. Mosca L., Appel L.J., Benjamin E.J., Berra K., Chandra-Strobos N., Fabunmi R.P., et al. American Heart Association Guidelines: evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004, 109:672-693.
15. Mosca L., Banka C.L., Benjamin E.J., Berra K., Bushnell C., Dolor R.J., et al. 2007 update: American Heart Association evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2007, 115:1481-1501.
16. Sowers M.R., La Pietra M.T. Menopause: its epidemiology and potential association with chronic diseases. Epidemiol Rev 1995, 17:287-302.
17. Bellamy L., Casas J.P., Hingorani A.D., Williams D.J. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007, 335:974.
18. Bassuk S.S., Manson J.E. Physical activity and cardiovascular disease prevention in women: a review of the epidemiologic evidence. Nutr Metab Cardiovasc Dis 2010, 20:467-473.
19. Rivellese A.A., Riccardi G., Vaccaro O. Cardiovascular risk in women with diabetes. Nutr Metab Cardiovasc Dis 2010, 20:474-480.
20. Donahue R.P., Dorn J.M., Stranges S., Swanson M., Hovey K., Trevisan M. Impaired fasting glucose and recurrent cardiovascular disease among survivors of a first acute myocardial infarction: evidence of a sex difference? the Western New York experience. Nutr Metab Cardiovasc Dis 2011, 21:504-511.
21. Wassertheil-Smoller S. Stroke in women. Nutr Metab Cardiovasc Dis 2010, 20:419-425.
22. Wann L.S., Curtis A.B., January C.T., Ellenbogen K.A., Lowe J.E., Estes N.A., et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010, 123:104-123.
23. Meisinger C., Heier M., Löwel H., Schneider A., Döring A. Sleep duration, sleep complaints and risk of myocardial infarction in middle-aged men and women from the general population. The MONICA/KORA Augsburg Cohort Study. Sleep 2007, 30:1121-1127.
24. Cappuccio F.P., Stranges S., Kandala N.B., Miller M.A., Taggart F.M., Kumari M., et al. Gender-specific associations of short sleep duration with prevalent and incident hypertension: the Whitehall II Study. Hypertension 2007, 50:694-701.
25. Stang A., Moebus S., Möhlenkamp S., Erbel R., Jöckel K.H. Gender-specific associations of short sleep duration with prevalent hypertension. Hypertension 2008, 51:e15-e16. Heinz Nixdorf Recall Study Investigative Group.
26. Stranges S., Dorn J.M., Cappuccio F.P., Donahue R.P., Rafalson L.B., Hovey K.M., et al. A population-based study of short sleep duration and hypertension: the strongest association may be in premenopausal women. J Hypertens 2010, 28:896-902.
27. Zhang B., Wing Y.K. Sex differences in insomnia: a meta-analysis. Sleep 2006, 29:85-93.
28. Stranges S., Tigbe W., Gómez-Olivé X.F., Thorogood M., Kandala N.-B. Sleep problems: an emerging global epidemic? Findings from the INDEPTH WHO-SAGE study among over 40,000 older adults from eight countries across Africa and Asia. Sleep 2012, 35:1173-1181.
29. Zito F., Di Castelnuovo A., De Curtis A., Dirckx C., Arnout J., Cappuccio F.P., et al. C reactive protein and its determinants in healthy men and women from European regions at different risk of coronary disease: the IMMIDIET Project. J Thromb Haemost 2008, 6:436-443. European Collaborative Group of Immidiet Project.
30. Santimone I., Di Castelnuovo A., De Curtis A., Spinelli M., Cugino D., Gianfagna F., et al. White blood cell count, sex and age are major determinants of heterogeneity of platelet indices in an adult general population: results from the MOLI-SANI Project. Haematologica 2011, 96:1180-1188. MOLI-SANI Project Investigators.
31. Berger J.S., Elliott L., Gallup D., Roe M., Granger C.B., Armstrong P.W., et al. Sex differences in mortality following acute coronary syndromes. J Am Med Assoc 2009, 302:874-882.
32. Vaccarino V., Parsons L., Peterson E.D., Rogers W.J., Kiefe C.I., Canto J. Sex differences in mortality after acute myocardial infarction. Arch Intern Med 2009, 169:1767-1774.
33. Healy B. The Yentyl syndrome. N Engl J Med 1991, 325:274-276.
34. Leuzzi C., Modena M.G. Coronary artery disease: clinical presentation, diagnosis and prognosis in women. Nutr Metab Cardiovasc Dis 2010, 20:426-435.
35. Collins S.D., Ahmad S., Waksman R. Percutaneous revascularization in women with coronary artery disease: we've come so far, yet have so far to go. Nutr Metab Cardiovasc Dis 2010, 20:436-444.
36. Klein L., Grau-Sepulveda M.V., Bonow R.O., Hernandez A.F., Williams M.V., Bhatt D.L., et al. Quality of care and outcomes in women hospitalized for heart failure. Circ Heart Fail 2011, 4:589-598.
37. Mosca L., Mochari-Greenberger H., Dolor R.J., Newby L.K., Robb K.J. Twelve-year follow-up of American women's awareness of cardiovascular disease risk and barriers to heart health. Circ Cardiovasc Qual Outcomes 2010, 3:120-127.
38. Melloni C., Berger J.S., Wang T.Y., Gunes F., Stebbins A., Pieper K.S., et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes 2010, 3:135-142.
39. Geller S.E., Koch A., Pellettieri B., Carnes M. Inclusion, analysis, and reporting of sex and race/ethnicity in clinical trials: have we made progress?. J Womens Health 2011, 20:215-220.
40. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998, 280:605-613.
41. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results of the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002, 288:321-333.
42. Stefanick M.L. Postmenopausal hormone therapy and cardiovascular disease in women. Nutr Metab Cardiovasc Dis 2010, 20:451-458.
43. Exploring the biological contributions to human health: does sex matter? 2001, The National Academies Press, Washington, DC. T.M. Wizeman, M.L. Pardue (Eds.).
44. Ridker P.M., Cook N.R., Lee I.-M., Gordon D., Gaziano J.M., Manson J.E., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005, 352:1293-1304.
45. Greving J.P., Buskens E., Koffijberg H., Algra A. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation 2008, 117:2875-2883.
46. Gutierrez J., Ramirez G., Rundek T., Sacco R.L. Statin therapy in the prevention of recurrent cardiovascular events. A sex-based meta-analysis. Arch Intern Med 2012, 172:909-919.
47. Mora S., Glynn R.J., Hsia J., MacFadyen J.G., Genest J., Ridker P.M. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010, 121:1069-1077.
48. Taylor F., Ward K., Moore T.H.M., Burke M., Davey Smith G., Casas J.P., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011, 1:CD004816.
49. Mihaylova B., Emberson J., Blackwell L., Keech A., Simes J., Barnes E.H., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590. Cholesterol Treatment Trialists' (CTT) Collaborators.
50. Lloyd-Jones D.M., Hong Y., Labarthe D., Mozaffarian D., Appel L.J., Van Horn L., on behalf of the American Heart Association Strategic Planning Task Force and Statistics Committee, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's Strategic Impact Goal through 2020 and beyond. Circulation 2010, 121:586-613.
51. Ford E.S., Li C., Zhao G., Pearson W.S., Capewell S. Trends in the prevalence of low risk factor burden for cardiovascular disease among United States adults. Circulation 2009, 120:1181-1188.
52. Lloyd-Jones D.M., Leip E.P., Larson M.G., D'Agostino R.B., Beiser A., Wilson P.W., et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006, 113:791-798.
53. Ridker P.M., Buring J.E., Rifai N., Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. J Am Med Assoc 2007, 297:611-619.
54. Marma A.K., Lloyd-Jones D.M. Systematic examination of the updated Framingham Heart Study general cardiovascular risk profile. Circulation 2009, 120:384-390.
55. Callinan J.E., Clarke A., Doherty K., Kelleher C. Legislative smoking bans for reducing secondhand smoke exposure, smoking prevalence and tobacco consumption. Cochrane Database Syst Rev 2010, 4:CD005992.
56. Puska P., Nissinen A., Tuomilehto J.T., Koskela K., McAlister A., Kotke T.E., et al. The community-based strategy to prevent coronary heart disease: conclusions from the ten years of the North Karelia Project. Annu Rev Public Health 1985, 6:147-193.
57. Guallar E., Banegas J.R., Blasco-Colmenares E., Jiménez F.J., Dallongeville J., Halcox J.P., et al. Estimated risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - the EURIKA Study. BMC Public Health 2011, 11:704.
58. Francke A.L., Smit M.C., de Veer A.J., Mistiaen P. Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Decis Mak 2008, 8:38.
59. Lewis W.R., Ellrodt A.G., Peterson E., Hernandez A.F., LaBresh K.A., Cannon C.P., et al. Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the Guidelines Quality-Improvement Program. Circ Cardiovasc Qual Outcomes 2009, 2:633-641.
60. Hsia J. Managing cardiovascular risk factors: trial evidence in women. Nutr Metab Cardiovasc Dis 2010, 20:445-450.
61. Manson J.E. Vitamin D and the heart: why we need large-scale clinical trials. Cleve Clin J Med 2010, 77:903-910.
62. Davis A.M., Vinci L.M., Okwuosa T.M., Chase A.R., Huang E.S. Cardiovascular health disparities: a systematic review of health care interventions. Med Care Res Rev 2007, 64(Suppl.):29S-100S.
63. Mathers C., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:2011-2030.